|
Total number of specimens = 2100
|
Previous anti-TB treatment status
|
|---|
|
New
|
Previously treated
|
Total
|
|---|
|
N
|
% (95% CI)
|
N
|
% (95% CI)
|
N
|
% (95% CI)
|
|---|
|
Total DST results
|
121
|
5.8
|
98
|
4.7
|
219
|
10.4
|
|
I
|
Any resistance to H
|
32
|
26.4 (19.4–35.4)
|
46
|
46.9 (37.1–56.8)
|
78
|
35.6 (29.3–42.0)
|
|
Any resistance to R
|
12
|
9.9 (5.8–16.5)
|
27
|
27.6 (18.7–36.4)
|
39
|
17.8 (12.7–22.9)
|
|
Any resistance to E
|
18
|
14.9 (9.6–22.3)
|
33
|
33.7 (24.3–43.0)
|
51
|
23.3 (17.7–28.9)
|
|
Any resistance to S
|
34
|
28.1 (20.9–36.7)
|
34
|
34.7 (25.3–44.1)
|
68
|
31.1 (24.9–37.2)
|
|
II
|
Resistance to H only
|
10
|
8.3 (4.7–15.3)
|
14
|
14.3 (7.1–20.9)
|
24
|
10.9 (6.8–15.1)
|
|
Resistance to R only
|
0
|
0 (0–0)
|
0
|
0 (0–0)
|
0
|
0 (0–0)
|
|
Resistance to E only
|
0
|
0 (0–0)
|
7
|
7.1 (1.9–12.1)
|
7
|
3.1 (0.9–5.5)
|
|
Resistance to S only
|
15
|
12.4 (8.6–21.4)
|
11
|
11.2 (4.8–17.2)
|
26
|
11.9 (7.6–16.2)
|
|
Total mono-resistance
|
25
|
20.7 (13.4–27.9)
|
32
|
32.6 (23.4–41.9)
|
57
|
26.02 (20.2-31.9)
|
|
III
|
H + R
|
1
|
0.8 (−0.8–2.8)
|
6
|
6.1 (1.3–10.7)
|
7
|
3.1 (0.9–5.5)
|
|
H + R + E
|
3
|
2.5 (0.04–6.04)
|
7
|
7.1 (1.9–12.1)
|
10
|
4.5 (1.8–7.3)
|
|
H + R + S
|
3
|
2.5 (0.04–6.04)
|
5
|
5.1 (0.7–9.3)
|
8
|
3.7 (1.2–6.2)
|
|
H + R + E + S
|
5
|
4.1 (1.1–8.9)
|
9
|
9.2 (3.3–14.7)
|
14
|
6.4 (3.2–9.6)
|
|
Total MDR
|
12
|
9.9 (4.6–15.2)
|
27
|
27.6 (18.7–36.4)
|
39
|
17.8 (12.7–22.9)
|
|
IV
|
H + E
|
4
|
3.3 (0.5–7.5)
|
3
|
3.1 (−0.4–6.4)
|
7
|
3.1 (0.9–5.5)
|
| |
H + S
|
5
|
4.1 (1.1–8.9)
|
2
|
2.04 (−0.8–4.8)
|
7
|
3.1 (0.9–5.5)
|
| |
H + E + S
|
1
|
0.8 (0.8–2.8)
|
3
|
3.1 (−0.4–6.4)
|
4
|
1.8 (0.1–3.6)
|
| |
R + E
|
0
|
0 (0–0)
|
0
|
0 (0–0)
|
0
|
0 (0–0)
|
| |
R + S
|
0
|
0 (0–0)
|
0
|
0 (0–0)
|
0
|
0 (0–0)
|
| |
R + E + S
|
0
|
0 (0–0)
|
0
|
0 (0–0)
|
0
|
0 (0–0)
|
| |
E + S
|
5
|
4.1 (1.1–8.9)
|
4
|
4.1 (0.12–7.9)
|
9
|
4.1 (1.5–6.7)
|
|
Total poly-resistance other than MDR
|
15
|
12.4 (6.8–18.3)
|
12
|
12.2 (5.8–18.7)
|
27
|
12.3 (8.0–16.7)
|
- CI – confidence interval, DST – drug susceptibility testing, E – ethambutol, H – isoniazid, R – rifampicin, S – streptomycin.
